Gemcitabine in Bone Sarcoma Resistant to Doxorubicin-Based Chemotherapy. (2000)

• Record Type: Journal Article
• Authors: Merimsky, Ofer; Meller, Isaac; Kollender, Yehuda; Issakov, Josephine; Flusser, Gideon; Inbar, Moshe
• Is Part Of: Sarcoma. Volume 4:Number 1/2(2000)
• Page Start: 7
• Page End: 10
• Publication Date: 2000
• Subjects: Sarcoma -- Periodicals; 616.994
• DOI: 10.1155/S1357714X00000025
• Languages: English
• ISSNs: 1357-714X

Abstract

Abstract : Subjects and Methods: Seven patients with progressive localized or metastatic chemo-resistant osteosarcoma were treated by gemcitabine.The protocol included gemcitabine 1000 mg/m2/w for 7 consecutive weeks, followed by 1 week rest. If no progression was observed, maintenance by gemcitabine 1000 mg/m2/w for 3 weeks every 28 days was given until failure was clinically or radiologically evident. Results. The true objective response rate was 0%. However, disease stabilization and clinical benefit response were observed in five patients (70%) for 13–96 weeks. Discussion. Postponing the inevitable death with a relatively non-toxic treatment, is, in our opinion, an important issue especially in young patients.Thus it may be justified and warranted to investigate the activity of gemcitabine in a larger group of patients with bone sarcomas.